{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T07:41:44Z","timestamp":1648539704123},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>We herein report the case of myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis with anti-glomerular basement membrane (anti-GBM) antibody positivity that successfully treated with mizoribine (MZR) as an immunosuppressive drug for remission maintenance therapy after the initiation of dialysis in addition to plasma exchange (PE) and glucocorticoid treatment to control the disease condition. A 79-year-old woman developed serious renal dysfunction and pulmonary alveolar hemorrhaging due to MPO\u2013ANCA and anti-GBM antibody double-positive vasculitis. She was started on hemodialysis and was treated with methylprednisolone (m-PSL) pulse therapy with PE, followed by oral prednisolone (PSL). The pulmonary alveolar hemorrhaging disappeared, and both antibody titers immediately decreased but then rose again. Thus, m-PSL pulse therapy performed again in combination with combined with MZR treatment. Her poor renal function was irreversible; however, this therapy decreased both antibody titers, and they did not increase again. The patient developed pancytopenia and hyperuricemia. It was considered likely that these conditions developed in association with MZR treatment. We, therefore, measured the patient\u2019s blood concentration of MZR, and the maintenance dose was finally set at 50\u00a0mg after each dialysis session. The patient\u2019s pancytopenia and hyperuricemia improved and PSL could be smoothly tapered. This is the first case report of the use of MZR for remission maintenance therapy in a patient on hemodialysis who was positive for both ANCA and anti-GBM antibodies. The findings suggest that MZR can be used safely and effectively in such cases.<\/jats:p>","DOI":"10.1007\/s13730-019-00423-2","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T14:05:58Z","timestamp":1571061958000},"page":"42-47","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchange"],"prefix":"10.1007","volume":"9","author":[{"given":"Yuki","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Fukunari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Uchiumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Awanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoaki","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"423_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"McAdoo SP, Tanna A, Hru\u0161kov\u00e1 Z, et al. Patient double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92:693\u2013702.","journal-title":"Kidney Int"},{"key":"423_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1744-9987.2009.00601.x","volume":"13","author":"M Tokunaga","year":"2009","unstructured":"Tokunaga M, Tamura M, Kabashima N, et al. A case report of steroid-resistant antineutrophil cytoplasmic antibody-related vasculitis successfully treated by mizoribine in a hemodialysis patient. Ther Apher Dial. 2009;13:77\u20139.","journal-title":"Ther Apher Dial"},{"key":"423_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13730-012-0050-1","volume":"2","author":"G Nakamura","year":"2013","unstructured":"Nakamura G, Homma N, Sakamaki Y, et al. Mizoribine as a safe and effective combined maintenance therapy with prednisolone for anti-neutrophil cytoplasmic antibody-associated vasculitis in a hemodialysis patient. CEN Case Rep. 2013;2:139\u201343.","journal-title":"CEN Case Rep"},{"issue":"3","key":"423_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176\u201381.","journal-title":"Semin Radiat Oncol"},{"key":"423_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000107803","volume":"107","author":"J Zhao","year":"2007","unstructured":"Zhao J, Yang R, Cui Z, et al. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract. 2007;107:56\u201362.","journal-title":"Nephron Clin Pract"},{"key":"423_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ajkd.2005.05.003","volume":"46","author":"A Rutgers","year":"2005","unstructured":"Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46:253\u201362.","journal-title":"Am J Kidney Dis"},{"key":"423_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1006\/bbrc.2000.3104","volume":"21","author":"S Takahashi","year":"2000","unstructured":"Takahashi S, Wakui H, Gustafsson JA, et al. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;21:87\u201392.","journal-title":"Biochem Biophys Res Commun"},{"key":"423_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/ndt\/gfi295","volume":"21","author":"Y Nishioka","year":"2006","unstructured":"Nishioka Y, Horita Y, Tadokoro M, et al. Mizoribine induces remission of relapsed ANCA-associated renal vasculitis. Nephrol Dial Transpl. 2006;21:1087\u20138.","journal-title":"Nephrol Dial Transpl"},{"key":"423_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2004.03.030","volume":"44","author":"K Hirayama","year":"2004","unstructured":"Hirayama K, Kobayashi M, Hashimoto Y, et al. Treatment With the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004;44:57\u201363.","journal-title":"Am J Kidney Dis"},{"key":"423_CR10","doi-asserted-by":"publisher","first-page":"681482","DOI":"10.1155\/2009\/681482","volume":"2009","author":"Y Kawasaki","year":"2009","unstructured":"Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.","journal-title":"Clin Dev Immunol"},{"key":"423_CR11","first-page":"197","volume":"23","author":"K Takada","year":"1985","unstructured":"Takada K, Yoshikawa H, Muranishi S, et al. Elimination characteristics of bredinin from patients serum in hemodialysis. Int J Clin Pharmacol Ther Toxicol. 1985;23:197\u20139.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"423_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1442-200X.2012.03733.x","volume":"54","author":"T Fuke","year":"2012","unstructured":"Fuke T, Abe Y, Hibino S, et al. Mizoribine requires individual dosing due to variation of bioavailability. Pediatr Int. 2012;54:885\u201391.","journal-title":"Pediatr Int"},{"key":"423_CR13","first-page":"3643","volume":"28","author":"K Sonda","year":"1996","unstructured":"Sonda K, Takahashi K, Tanabe K, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transpl Proc. 1996;28:3643\u20138.","journal-title":"Transpl Proc"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00423-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-019-00423-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00423-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T23:28:54Z","timestamp":1602545334000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-019-00423-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["423"],"URL":"https:\/\/doi.org\/10.1007\/s13730-019-00423-2","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"12 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not report any studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}